Meta- Analysis of positive and negative symptoms reveals schizophrenia modifier genes

Schizophrenia Bulletin

Volumn 42, Issue 2, 2016, Pages 279-287

  Edwards, Alexis C ^a   Bigdeli, Tim B ^a   Docherty, Anna R ^a   Bacanu, Silviu ^a   Lee, Donghyung ^a   De Candia, Teresa R ^b   Moscati, Arden ^a   Thiselton, Dawn L ^h   Maher, Brion S ^c   Wormley, Brandon K ^a   Walsh, Dermot ^d   O'neill, Francis A ^e   Kendler, Kenneth S ^a   Riley, Brien P ^a   Fanous, Ayman H ^a,f,g  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d HEALTH RESEARCH BOARD   (Ireland)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Health Diagnostic Laboratory Inc   (United States)

Author keywords

Clinical heterogeneity; Meta Analysis; Modifier genes; Negative symptoms; Positive symptoms; Schizophrenia

Indexed keywords

ARTICLE; GENE LOCUS; GENE ONTOLOGY; GENETIC MARKER; GENETIC RISK; GENOME-WIDE ASSOCIATION STUDY; HEREDITY; HUMAN; META ANALYSIS; MODIFIER GENE; NEGATIVE SYNDROME; ONTOLOGY; PEDIGREE; PHENOTYPE; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; PATHOPHYSIOLOGY;

HUMANS; SCHIZOPHRENIA;

EID: 84964856547     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv119     Document Type: Article

References (68)

1. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382:1575-1586.
2. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta- Analysis of twin studies. Arch Gen Psychiatry. 2003;60:1187-1192.
3. Lichtenstein P, Yip BH, Bjork C, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: A population-based study. Lancet. 2009;373:234-239.
4. MacDonald AW, Schulz SC. What we know: findings that every theory of schizophrenia should explain. Schizophr Bull. 2009;35:493-508.
5. Peralta V, Cuesta MJ. How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment. Schizophr Res. 2001;49:269-285.
6. McGrath JA, Avramopoulos D, Lasseter VK, et al. Familiality of novel factorial dimensions of schizophrenia. Arch Gen Psychiatry. 2009;66:591-600.
7. Fanous AH, Kendler KS. Genetic heterogeneity, modifier genes, and quantitative phenotypes in psychiatric illness: searching for a framework. Mol Psychiatry. 2005;10:6-13.
8. Fanous AH, Neale MC, Webb BT, et al. A genome-wide scan for modifier loci in schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:589-595.
9. Wilcox MA, Faraone SV, Su J, Van Eerdewegh, P, Tsuang MT. Genome scan of three quantitative traits in schizophrenia pedigrees. Biol Psychiatry. 2002;52:847-854.
10. Bergen SE, Fanous AH, Kuo PH, et al. No association of dysbindin with symptom factors of schizophrenia in an Irish case-control sample. Am J Med Genet B Neuropsychiatr Genet. 2009;153B:700-705.
11. Suchanek R, Owczarek A, Paul-Samojedny M, et al. BDNF val66met polymorphism is associated with age at onset and intensity of symptoms of paranoid schizophrenia in a Polish population. J Neuropsychiatry Clin Neurosci. 2013;25:88-94.
12. Tovilla-Zarate C, Medellin BC, Fresan A, et al. No association between catechol-o-methyltransferase Val108/158Met polymorphism and schizophrenia or its clinical symptomatology in a Mexican population. Mol Biol Rep. 2013;40:2053-2058.
13. Fanous AH, Zhou B, Aggen SH, et al. Genome-wide association study of clinical dimensions of schizophrenia: polygenic effect on disorganized symptoms. Am J Psychiatry. 2012;169:1309-1317.
14. Cummings E, Donohoe G, McDonald C, et al. Clinical symptomatology and the psychosis risk gene ZNF804A. Schizophr Res. 2010;122:273-275.
15. DeRosse P, Funke B, Burdick KE, et al. Dysbindin genotype and negative symptoms in schizophrenia. Am J Psychiatry. 2006;163:532-534.
16. DeRosse P, Funke B, Burdick KE, et al. COMT genotype and manic symptoms in schizophrenia. Schizophr Res. 2006;87:28-31.
17. Fanous AH, Amdur RL, O'Neill FA, Walsh D, Kendler KS. Concordance between chart review and structured interview assessments of schizophrenic symptoms. Compr Psychiatry. 2012;53:275-279.
18. Fanous AH, Neale MC, Webb BT, et al. Novel linkage to chromosome 20p using latent classes of psychotic illness in 270 Irish high-density families. Biol Psychiatry. 2008;64:121-127.
19. Fanous AH, van den Oord, EJ, Riley BP, et al. Relationship between a high-risk haplotype in the DTNBP1 (Dysbindin) gene and clinical features of schizophrenia. Am J Psychiatry 2005;162:1824-1832.
20. Bigdeli TB, Maher BS, Zhao Z, et al. Comprehensive genebased association study of a chromosome 20 linked region implicates novel risk loci for depressive symptoms in psychotic illness. PLoS One. 2011;6:e21440.
21. Fanous AH, Zhao Z, van den Oord, EJ, et al. Association study of SNAP25 and schizophrenia in Irish family and casecontrol samples. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:663-674.
22. Cuthbert BN, Insel TR. Toward new approaches to psychotic disorders: The NIMH Research Domain Criteria project. Schizophr Bull. 2010;36:1061-1062.
23. Ayalew M, Le-Niculescu H, Levey DF, et al. Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol Psychiatry. 2012;17:887-905.
24. Farmer AE, Jones I, McGuffin P. Defining schizophrenia: operational criteria. J Mental Health. 1993;2:209-222.
25. Bigdeli TB, Bacanu SA, Webb BT, et al. Molecular validation of the schizophrenia spectrum. Schizophr Bull. 2014;40:60-65.
26. Irish Schizophrenia Genomics Consortium, Wellcome Trust Case Control Consortium. Genome-wide association study implicates HLA-C∗01:02 as a risk factor at the major histocompatibility complex locus in schizophrenia. Biol Psychiatry. 2012;72:620-628.
27. Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. Nat Methods. 2012;9:179-181.
28. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 2009;5:e1000529.
29. The 1000 Genomes Project Consortium, Abecasis GR, Auton A, et al. An integrated map of genetic variation from 1, 092 human genomes. Nature. 2012;491:56-65.
30. Howie B, Marchini J, Stephens M. Genotype imputation with thousands of genomes. G3 (Bethesda). 2011;1:457-470.
31. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient metaanalysis of genomewide association scans. Bioinformatics. 2010;26:2190-2191.
32. Li MX, Gui HS, Kwan JS, Sham PC. GATES: A rapid and powerful gene-based association test using extended Simes procedure. Am J Hum Genet. 2011;88:283-293.
33. Li MX, Kwan JS, Sham PC. HYST: A hybrid set-based test for genome-wide association studies, with application to protein-protein interaction-based association analysis. Am J Hum Genet. 2012;91:478-488.
34. Neale BM, Sham PC. The future of association studies: gene-based analysis and replication. Am J Hum Genet. 2004;75:353-362.
35. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Stat Soc Ser B (Stat Method). 1995;57:289-300.
36. Kamburov A, Pentchev K, Galicka H, Wierling C, Lehrach H, Herwig R. ConsensusPathDB: Toward a more complete picture of cell biology. Nucleic Acids Res. 2011;39:D712-D717.
37. Purcell S, Neale B, Todd-Brown K, et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559-575.
38. Mailman MD, Feolo M, Jin Y, et al. The NCBI dbGaP database of genotypes and phenotypes. Nat Genet. 2007;39:1181-1186.
39. Lee D, Bigdeli TB, Riley BP, Fanous AH, Bacanu SA. DIST: direct imputation of summary statistics for unmeasured SNPs. Bioinformatics. 2013;29:2925-2927.
40. International Schizophrenia Consortium, Purcell SM, Wray NR, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748-752.
41. Aberg KA, Liu Y, Bukszar J, et al. A comprehensive family- based replication study of schizophrenia genes. JAMA Psychiatry. 2013;70:573-581.
42. Sherva R, Tripodis Y, Bennett DA, et al. Genome-wide association study of the rate of cognitive decline in Alzheimer's disease. Alzheimers Dement. 2014;10:45-52.
43. Calboli FC, Tozzi F, Galwey NW, et al. A genome-wide association study of neuroticism in a population-based sample. PLoS One. 2010;5:e11504.
44. Ryan SG, Dixon MJ, Nigro MA, et al. Genetic and radiation hybrid mapping of the hyperekplexia region on chromosome 5q. Am J Hum Genet. 1992;51:1334-1343.
45. Shiang R, Ryan SG, Zhu YZ, Hahn AF, O'Connell P, Wasmuth JJ. Mutations in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia. Nat Genet. 1993;5:351-358.
46. Gao X, Ge L, Shao J, et al. Tudor-SN interacts with and co-localizes with G3BP in stress granules under stress conditions. FEBS Lett. 2010;584:3525-3532.
47. Kwon S, Zhang Y, Matthias P. The deacetylase HDAC6 is a novel critical component of stress granules involved in the stress response. Genes Dev. 2007;21:3381-3394.
48. Hull J, Hindy ME, Kehoe PG, Chalmers K, Love S, Conway ME. Distribution of the branched chain aminotransferase proteins in the human brain and their role in glutamate regulation. J Neurochem. 2012;123:997-1009.
49. Malki K, Campbell J, Davies M, et al. Pharmacoproteomic investigation into antidepressant response in two mouse inbred strains. Proteomics. 2012;12:2355-2365.
50. Du Y, Zou Y, Yu W, et al. Expression pattern of sorting Nexin 25 in temporal lobe epilepsy: A study on patients and pilocarpine- induced rats. Brain Res. 2013;1509:79-85.
51. Sagara J, Arata T, Taniguchi S. Scapinin, the protein phosphatase 1 binding protein, enhances cell spreading and motility by interacting with the actin cytoskeleton. PLoS One. 2009;4:e4247.
52. Farghaian H, Chen Y, Fu AW, et al. Scapinin-induced inhibition of axon elongation is attenuated by phosphorylation and translocation to the cytoplasm. J Biol Chem. 2011;286:19724-19734.
53. Kato M, Nakamura M, Ichiba M, et al. Mitochondrial DNA deletion mutations in patients with neuropsychiatric symptoms. Neurosci Res. 2011;69:331-336.
54. Buonanno A, Fischbach GD. Neuregulin and ErbB receptor signaling pathways in the nervous system. Curr Opin Neurobiol. 2001;11:287-296.
55. Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002;71:877-892.
56. Williams NM, Preece A, Spurlock G, et al. Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia. Mol Psychiatry. 2003;8:485-487.
57. Munafo MR, Thiselton DL, Clark TG, Flint J. Association of the NRG1 gene and schizophrenia: A meta- Analysis. Mol Psychiatry. 2006;11:539-546.
58. Kukshal P, Bhatia T, Bhagwat AM, et al. Association study of neuregulin-1 gene polymorphisms in a North Indian schizophrenia sample. Schizophr Res. 2013;144:24-30.
59. Thiselton DL, Webb BT, Neale BM, et al. No evidence for linkage or association of neuregulin-1 (NRG1) with disease in the Irish study of high-density schizophrenia families (ISHDSF). Mol Psychiatry. 2004;9:777-783; image 729.
60. Munafo MR, Attwood AS, Flint J. Neuregulin 1 genotype and schizophrenia. Schizophr Bull. 2008;34:9-12.
61. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001;58:165-171.
62. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia- Associated genetic loci. Nature. 2014;511:421-427.
63. Benros ME, Mortensen PB, Eaton WW. Autoimmune diseases and infections as risk factors for schizophrenia. Ann N Y Acad Sci. 2012;1262:56-66.
64. Thoma P, Daum I. Comorbid substance use disorder in schizophrenia: A selective overview of neurobiological and cognitive underpinnings. Psychiatry Clin Neurosci. 2013;67:367-383.
65. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry. 1991;148:1474-1486.
66. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III- The final common pathway. Schizophr Bull. 2009;35:549-562.
67. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17:1206-1227.
68. Ruderfer DM, Fanous AH, Ripke S, et al. Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. Mol Psychiatry. 2014;19:1017-1024.